EE33 Cost-Effectiveness of Aducanumab, Lecanemab, and Donanemab for Early Alzheimer Disease in the US

Abstract

Authors

F Haile K Lee

Full Text Cite This Article
Back to Volume 27, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×